KRAS and pachyonychia congenita: Mutation of KRAS is one of the most common alterations in both high- and low-risk groups, being present in approximately 90% of PC patients, and is regarded as the major genetic initiating event in oncogenesis by influencing the TME and cell proliferation, apoptosis, autophagy, and metabolism (Bailey et al., 2016; Chan-Seng-Yue et al., 2020; Pereira et al., 2022).